We are live on ! Find out more

iShares Biotechnology ETF

IBB

Market cap $10.4B

205.36 USD

-1.71

0.83%

At close Updated Sep 18, 11:38 AM EDT

1 day

-0.83%

5 days

0.81%

1 month

0.88%

3 months

18.27%

6 months

25.39%

Year to date

21.51%

1 year

42.98%

5 years

20.86%

10 years

111.34%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 43.8%

Neutral 37.5%

Negative 18.8%

Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets

With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets.

Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets

24/7 Wall Street

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

CNBC Television

Emily Field: Large pharma companies are going to continue looking at biotech

Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.

Emily Field: Large pharma companies are going to continue looking at biotech

24/7 Wall Street

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday.

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

‘Never Happened in History,' Ex-Bridgewater Exec Warns AI Market Is Priced to Perfection

Bob Elliott, the former Bridgewater Associates executive and CIO of Unlimited, says the rally in artificial-intelligence stocks is built on an economic scenario that depends on unprecedented productivity growth, aggressive household dissaving and a circular flow of capital among technology companies.

‘Never Happened in History,' Ex-Bridgewater Exec Warns AI Market Is Priced to Perfection

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excluding Japan was little changed after swinging between gains and losses.

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

See News Rankings

Price charts implemented using Lightweight Charts™